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Summary. Background: Tissue factor (TF) is the essential cell surface initiator of coagulation, and mediates cell signaling through protease-activated receptor (PAR) 2. Having a diverse cellular distribution, TF is involved in many biological pathways and pathologies. Our earlier work identified host cell-derived TF on the envelope covering several viruses, and showed its involvement in enhanced cell infection in vitro. Objective: In the current study, we evaluated the in vivo effects of virus surface TF on infection and on the related modulator of infection PAR2. Methods: With the use of herpes simplex virus type 1 (HSV1) as a model enveloped virus, purified HSV1 was generated with or without envelope TF through propagation in a TF-inducible cell line. Infection was studied after intravenous inoculation of BALB/c, C57BL/ 6J or C57BL/6J PAR2 knockout mice with 5 9 10 5 plaque-forming units of HSV1, mimicking viremia. Three days after inoculation, organs were processed, and virus was quantified with plaque-forming assays and quantitative real-time PCR. Results: Infection of brain, lung, heart, spinal cord and liver by HSV1 required viral TF. Demonstrating promise as a therapeutic target, virus-specific anti-TF mAbs or small-molecule inhibitors of coagulation inhibited infection. PAR2 modulates HSV1 in vivo as demonstrated with PAR2 knockout mice and PAR2 agonist peptide. Conclusion: TF is a constituent of many permissive host cell types. Therefore, the results presented
Introduction
Tissue factor (TF) is a multifunctional transmembrane receptor that is essential for mammalian life [1] [2] [3] . It is critically positioned as a cofactor that enhances the protease activated factor VII (FVIIa) at the intersection of blood coagulation and the vascular inflammatory response. The activation of FX to activated FX (FXa) is triggered by TF-FVIIa, which initiates the procoagulant response to vascular damage. As a constituent of the nascent TF-FVIIa-FXa complex, TF also coordinates protease-activated receptor (PAR) 2-mediated cell signaling, with diverse effects on health and disease, including angiogenesis, tissue repair, diabetes, pain, cell proliferation, and innate immunity [4] [5] [6] [7] [8] [9] . To localize these protease-activating and cell-signaling functions, TF activity is restricted to sites where cells are stimulated, such as by vascular damage, and on the surfaces of related microvesicles [10] [11] [12] . Adding to the functional repertoire of TF, our earlier work identified its constitutive activity and antigen on the host cell-originated envelope structure of three herpesvirus family members, i.e. herpes simplex virus type 1 (HSV1), herpes simplex virus type 2, and cytomegalovirus, each of which was purified from several cultured cell types [13] . These viruses thus bypass the physiological localization of coagulation protease activation by TF, which helps to explain their reported links to vascular disease [14] [15] [16] [17] .
To investigate the effects of virus envelope TF on cell infection, we used HSV1, which establishes latency with frequent reactivation and a coincident inflammatory response, as a model envelope virus [18] . Although it is commonly recognized as the 'cold sore virus', HSV1 has numerous effects on health. In addition to its correlation with vascular disease [14] [15] [16] [17] , HSV1 is the leading cause of infectious blindness [19] , sporadic encephalitis [20] , and genital herpes [21] , and is associated with intestinal dysregulation [22] . As TF is multifunctional, we previously explored the role of envelope TF in infection by using purified HSV1 that either bears host cell-derived TF (HSV1/TF + ) or is deficient in TF (HSV/TF À ) [23] . These in vitro studies showed that infection of endothelial cell monolayers under serum-free culture conditions was enhanced by the availability of virus envelope TF, and that the mechanism involved PAR2. Therefore, we hypothesized that in vivo infection may be affected by viral TF facilitating coagulation enzyme activation. In the current study, we investigated the effects of TF on the surface of bloodborne HSV1 in mice. Against the conventional paradigm that virus-encoded gene products primarily control virus surface-host communication and thus infectivity, we report that the availability of host-encoded TF as a constituent of the HSV1 envelope induces permissiveness to infection in mice.
Materials and methods

Virus production
HSV1/TF + and HSV/TF À were propagated in TF-inducible human melanoma cells [24] , and purified as previously described [23] . Comparable in vitro plaque-forming units (PFUs) per virus particle (VP) number were ensured [25] . Thus, each virus preparation had similar numbers of VPs per milliliter and PFUs per milliliter. This was achieved by introducing UV-inactivated virus into higher-PFU/VP preparations. Viruses were purified by sucrose gradient ultracentrifugation, quality-assured for lack of cellular debris, and quantified to derive VP per milliliter by negative-staining electron microscopy [25] . All cells were shown to be mycoplasma-free. To derive the number of infectious viruses, plaque assays on African green monkey kidneys cells (Vero, CCL-81; ATCC, Manassas, VA, USA) were conducted, as previously described [23] .
Animals
Animal experiments were approved by the Animal Care Committee at the University of British Columbia. Two mouse strains were compared: BALB/c mice, which are relatively vulnerable to infection, and C57BL/6J mice, which are relatively resistant [26, 27] . Eight-week-old female BALB/c or wild-type C57BL/6J mice were obtained from Jackson Laboratories (Bar Harbor, ME, USA). Additional experiments were conducted with wildtype C57BL/6J and age-matched and sex-matched PAR2 knockout (KO) (PAR2 À ) mice backcrossed for nine generations with C57BL/6J [28] . The number of mice in each experiment was chosen to provide 95% statistical power with a 5% error level. Mice were randomly allocated to each treatment group, and excluded from the study if injection of the virus was unsuccessful. , respectively. Previous reports have shown that new HSV1 production is detectable 3 days after inoculation of BALB/c mice [38, 39] . As this timing also enables clearance of the initial virus inoculum [38, 39] , the experimental endpoint used in the current study was 3 days after inoculation. The lungs, heart, liver, spinal cord and brain were surgically removed, frozen on dry ice, and stored at À 80°C. Prior to analysis, individual organs were weighed into 1 mL of cell medium, and processed through a 40-lm cell strainer to separate the larger cell debris. The lysate was used to infect Vero cell monolayers, and quantified with a standard plaque assay to determine the amount of infectious virus (PFUs) per gram of tissue.
Quantitative real-time PCR (qRT-PCR) analysis
The cell lysate was also used in some cases to determine the amount of viral genome per mg of tissue by qRT-PCR. Viral DNA was extracted with the QIAamp cador Pathogen Mini Kit (Qiagen, Montreal, Quebec, Canada) according to the manufacturer's protocol. Standard curve samples were prepared with purified HSV1 DNA and mouse lung genomic DNA as a source of the b-actin gene (Actb). The standard curve samples were run in triplicate with the wells having 10 1 -10 9 copies of DNA. The limit of quantification for the qRT-PCR assay was 10 copies of HSV-1 DNA. For the determination of viral titer, mouse organ samples were run in triplicate along with standardized samples. Those that did not yield a positive signal in duplicate wells following 40 cycles of amplification were considered to be negative. The HSV1 DNA copy number per gram of tissue sample was normalized and expressed as log 10 DNA copies per 10 5 Actb copies. The primers for HSV1 amplified from mouse organs were as follows:
0 -GCAGGTGTAGAAGTACCTCTCGGG-3 0 ; and probe, 5
0 -ACTGCAAGGTTCGCAAGGCGACCAA-3 0 . For the Actb housekeeping gene, primers and FAM probe reporter dye were obtained from TaqMan Assay Mm00607939_s1 (Applied Biosystems, Foster City, CA, USA). Reactions were performed on 2 lL of DNA in 20 lL of reaction mixture with TaqMan Fast Advanced gene expression master mix, and qRT-PCR was performed on an ABI 7900HT Sequence Detection System by selecting the appropriate detector (Applied Biosystems). The cycle program was set at 50°C for 2 min and 95°C for 20 s, followed by 40 cycles of 95°C for 1 s and 60°C for 20 s. Data were analyzed with SDS 2.3 software.
Statistical analysis
The data are presented as the mean AE standard error of the mean (SEM) of at least four separate mice, each measured in triplicate, and experiments were conducted on at least two different litters. Data are presented as mean AE SEM, and Student's t-test (two-tailed distribution) was used to calculate P-values.
Results
Infection of Th2-immunodominant mice is enhanced by TF on HSV1
The potential effect of virus surface TF on infection was evaluated in vivo by comparing HSV1/TF + with HSV1/ TF À infection of BALB/c mice. This strain of mouse is permissive to infection because the immune response is largely driven by Th2 cell pathways and is characterized by high antibody titers [26, 27, 40] . Three days after inoculation, five organs were recovered and evaluated for virus infiltration: heart, lung, spinal cord, brain, and liver. HSV1 was quantified with plaque-forming assays, and each organ was shown to accumulate infectious virus. Infectivity was found to be highly dependent on the presence of envelope TF (Fig. 1A ). These functional data were supported by measurement of the virus genome copy number by qRT-PCR (Fig. 1A) , which showed that production of infectious virus was inhibited when envelope TF was absent. Therefore, envelope TF enhances the infection cycle at or prior to DNA replication. To further address the role of viral TF, BALB/c mice received a combination of three well-characterized anticoagulant mAbs [30, 32] that recognize different epitopes on only the human TF incorporated into the purified HSV1 envelope . This treatment reduced the infectious HSV1 (Fig. 1B) and total virus genome copy number (Fig. 1B) detectable in each organ. Comparable results were observed with a single TF-specific antibody, 5G9 ( Fig. 1B; 1-aTF) , excluding the possibility that multivalent antibody presentation may facilitate complement-mediated virus inactivation. The lack of difference between the triple and single anti-TF treatments suggests that only one of the functional regions of TF requires inhibition for an antiviral effect, in this case FX binding. A human anti-TF mAb that has no effect on the procoagulant cofactor function of TF but inhibits PAR2 signaling was evaluated ( Fig. 1B; aSignal). At 3 days after infection, this antibody had a minimal effect on the amount of infectious virus measured in each organ. These plaque data were corroborated by qRT-PCR (Fig. 1B) . Furthermore, an isotype control injected at the same concentration of specific antibody had no effect ( Fig. 1B; mIgG) .
Infection of BALB/c mice is inhibited by anticoagulants
The involvement of TF in FXa production and the consequent downstream generation of thrombin and effects on HSV1 infection of BALB/c mice were investigated with specific coagulation protease inhibitors. As infection of BALB/c with HSV1/TF À ( Fig. 1A ; Virus, TF À ) resulted in mostly undetectable levels of infection, only HSV1/ TF + mice were evaluated. Figure 2 shows that all three anticoagulants studied blocked HSV1/TF + infection. These were: hirudin, a thrombin-specific inhibitor; NAPc2, which inhibits FXa and the TF-FVIIa-FXa complex; and apixaban, a small-molecule FXa-directed oral anticoagulant therapeutic. All mice appeared to be healthy with no evidence of spontaneous bleeding up to the experimental endpoint (3 days).
Infection of Th1-immunodominant mice (C57BL/6J) is enhanced by TF on HSV1
Mouse strains differ in their susceptibility to virus infection [41, 42] . In contrast to BALB/c mice, C57BL/6J mice are resistant to virus infection, because their immune response is predominantly Th1-driven, triggering a rapid innate immune response that involves phagocytic cells [26, 27] . Predictably, we found that infection of C57BL/6J mice with HSV1/TF + was reduced by approximately one log in most organs studied relative to Th2-immunodominant BALB/c mice (Fig. 3 , HSV/TF + , as compared with Fig. 1A , HSV/ TF + ). Nevertheless, detection of infectious HSV1 by plaque assays 3 days after inoculation of C57BL/6J mice was enhanced in each organ studied when TF was available on the virus surface ( Fig. 3 ; HSV1/TF + as compared with HSV1/TF À ). The exception was the brain, which was not permissive to infection with HSV/TF + or HSV1/TF À , presumably because of the added protective effects of the blood-brain barrier. Interestingly, unlike the PFU measurement of virus infection, the genome copy number for infection of C57BL/6J mice was not appreciably dependent on the viral TF phenotype (Fig. 3) . Thus, the presence of envelope TF increases the proportion of infectious virus relative to non-infectious virus that is produced in C57BL/6J mice, suggesting inhibition resulting from the lack of envelope TF is during, or post viral DNA replication.
Infection of C57BL/6J mice is enhanced by PAR2 deficiency ; n = 13) HSV1 via the tail vein. Three days after infection, the mice were processed and the amounts of infectious virus (Virus; PFUs per milligram) and HSV1 genetic material (Genome; genome copies per milligram) were determined. (B) Additional experiments were conducted after preimmunization of mice with a mixture of three anti-TF IgG 1 mAbs, i.e. 5G9, 9C3, and 6B4 (3-aCoag; at 0.33 mg each per mouse; n = 10), 5G9 alone (1-aCrag; 1 mg per mouse; n = 6), or 10H10 alone (aSignal; 1 mg per mouse; n = 6), 4 h prior to injection of the virus. Purified anti-Simian virus 40 large T antigen (mIgG; 1 mg per mouse; n = 8) was used as an irrelevant monoclonal IgG 1 subclassmatched negative control. Gray bars represent data from HSV1/TF + as depicted in (A). In all panels, data are expressed as mean AE standard error of the mean. As determined with Student's t-test, **P ≤ 0.05 and *P ≤ 0.10 as compared with the TF + virus.
Deleting PAR2 expression in C57BL/6J mice caused an increase in HSV1 infection in the heart, lung, brain, and liver ( Fig. 4 ). These data were corroborated by measuring genome copy number (Fig. 4) , except for the spinal cord, which may reflect the accumulation of noninfectious virus because of the specific mechanisms involved in neurotropism. These combined data indicate that PAR2 competence in wild-type mice is protective against infectious virus production.
Although C57BL/6J mice are relatively resistant to infection, and more so in the absence of viral TF, we studied the effect of PAR2 deficiency in mice combined with the lack of TF on the virus surface (Fig. 4) . When TF was excluded from the virus surface and infection in PAR2 KO mice was followed, diminished infection was anticipated, as envelope TF was important for HSV1 infection of C57BL/6J wild-type mice (Fig. 3) . Consistently, heart, lung, spinal cord, brain and liver trended towards reduced infection with HSV1/TF À when compared with HSV1/TF + , as determined by virus plaque assays or genome expression, when PAR2 was genetically deleted.
Infection of BALB/c mice is inhibited by PAR2-activating peptide
Synthetic PAR2ap, which triggers G-protein-coupled cell signaling, was added to the HSV1/TF + inoculum to study the effect of a systemic gain-of-function on PAR2 stimulation. As HSV1 infection is weak in C57BL/6J mice, and the results obtained with genetically deficient mice suggested that PAR2 activation in wild-type mice will lead to inhibition of infection, the Th2-immunodominant strain was used. Plaque formation assays revealed that PAR2ap attenuated infection in BALB/c mice by 80-90% when measured 3 days after inoculation (Fig. 5 ).
Discussion
Relatively little is known about the function of virus envelope constituents obtained from the host cell [43, 44] . In the current study, we investigated the effects of host cell membrane-derived HSV1 envelope TF on hemostasis and infection in vivo. In a model of viremia in which a sublethal dose of purified HSV1/TF + or HSV1/TF À was injected into the tail vein, two mouse strains demonstrated that viral TF contributes greatly to infection regardless of whether a Th1 or Th2 immune response is , n = 18), or apixaban (1 mg kg À1 , n = 18), via the tail vein. In each case, 3 days after infection, the mice were processed, and the amount of infectious virus (PFUs per milligram) was determined in each organ. In all panels, data are expressed as mean AE standard error of the mean. As determined with Student's t-test, **P ≤ 0.05 as compared with the TF + virus alone.
prevalent. The greatest effect was in the higher-susceptibility Th2-immunodominant strain, BALB/c, in which envelope TF was obligatory for detection of infectious HSV1 in all organs tested, i.e. heart, lung, spinal cord, brain, and liver. Significant enhancement attributable to viral TF was also observed in C57BL/6J mice, which favor a Th1 immune response, and are consequently less vulnerable to HSV1 infection than BALB/c mice. Therefore, the physiological initiator of coagulation, TF, associated with the HSV1 envelope is a previously unrecognized host cell-derived constituent that serves an important function during the in vivo virus infection cycle.
The effect of TF on the virus was further investigated with species-specific mAbs that recognize the human TF on HSV1/TF + but not the TF intrinsic to the mouse [45] . These well-characterized anticoagulant antibodies [30] reduced the amount of infectious virus in heart, lung, liver, spinal cord, brain, and liver, identifying envelope TF function as an antiviral target. This possibility was supported by the effects of NAPc2, which forms a quaternary inhibition complex with TF, FXa, and FVIIa [33, 46] , and thus inhibits all extrinsic pathway coagulation factors simultaneously. NAPc2 was more effective than the TF-specific anticoagulant antibodies, and reduced the amount of infectious HSV1 in all tissues evaluated to a nearly undetectable level. However, unlike the antibodies used here, NAPc2 affects not only viral TF but also the TF complexes intrinsic to the mouse, which may be involved in the virus infection process.
TF is found throughout the body, owing to its prevalent constitutive expression by fibroblasts, pericytes, smooth muscle cells, epithelial cells, astrocytes and cardiomyocytes, and inducibility on other cells, such as endothelial and monocyte lineage cells [3] . Thus, TFbearing cells are permissive to infection by many clinically important enveloped viruses from different virus families, including Ebola [47] , influenza [48] , HIV [49] , dengue [50] , Zika [51] , hepatitis C [52] and others. As a pervasive host cell-encoded transmembrane protein, TF is conceivably a common in vivo envelope constituent. As an example, NAPc2 has been used to successfully treat infection of rhesus monkeys with the filovirus Ebola [53, 54] , although TF being present on the virus envelope was not considered by these authors. Thus, in combination with our current in vivo and prior in vitro data [13] , these findings indicate that TF may participate across numerous virus families because of its wide cell Fig. 3 . Infection of Th1-immunodominant mice (C57BL/6J) is enhanced by tissue factor (TF) on herpes simplex virus type 1 (HSV1). Eight-week-old female C57BL/6J mice were inoculated intravenously with 5 9 10 5 plaque-forming units (PFUs) of either TF-competent (TF + ; n = 7) or TF-deficient (TF À ; n = 8) HSV1 via the tail vein. Three days after infection, the mice were processed, and the amounts of infectious virus (Virus; PFUs per milligram) and HSV1 genetic material (Genome; genome copies per milligram) were determined. In all panels, data are expressed as mean AE standard error of the mean. As determined with Student's t-test, **P ≤ 0.05 and *P ≤ 0.10 as compared with the TF + virus. distribution, thereby serving as a broad-spectrum antienvelope virus target.
Thrombin is the ultimate coagulation protease, and is produced once TF mediates FXa generation. Facilitating PAR1, PAR3 and PAR4 activation, feedback regulation of hemostasis, and clot formation [55, 56] , thrombin is a major hemostasis regulator. To investigate the possibility that thrombin has an additional function, HSV1 infection was measured in the presence of the highly specific thrombin inhibitor hirudin. Indeed, hirudin attenuated in vivo infection, indicating that the virus exploits thrombin activity for infection. However, inhibition of infection was also facilitated by NAPc2, suggesting that upstream FXa may also be involved. Therefore, the effect of an FXa-directed anticoagulant was investigated. At the approximate therapeutic dose used in humans (1.0 mg kg À1 versus~0.4 mg kg
À1
), apixaban was as effective as NAPc2 in reducing HSV1 infection, suggesting that inhibition of FXa may be the dominant antiviral effector. Although avoiding the induction of bleeding may be a challenge, an unforeseen application of apixaban, or other routinely used anticoagulant therapeutics, may be to control virus infection.
We previously reported that the infection of cultured human endothelial cell monolayers with HSV1 was enhanced by a brief pretreatment with PAR2ap and inhibited by a TF-specific antibody (10H10) that disrupts TF-mediated PAR2 signaling [23] . The experimental conditions excluded the participation of plasma proteins (e.g. activated coagulation proteases), and immune and other cells that would normally be present during infection in vivo. To investigate the biological role of PAR2 in HSV1 infection, the current study showed that C57BL/6J PAR2 KO mice were more vulnerable to infection 3 days after inoculation. Therefore, PAR2 competence protected the animal against HSV1 infection. PAR2ap predictably inhibited infection in mice. This involvement of PAR2 is probably attributable to the recruitment of innate immune-responsive cells, but is opposite to the enhancement observed in vitro.
Although TF stimulates PAR2 [8] , the results reported here suggest that the increased infection in mice caused by viral TF is not explained by stimulation of PAR2 intrinsic to the mouse. A disconnect between viral TF and PAR2 in vivo is further supported by the finding that 10H10, which is specific for the human TF [45] on the virus surface, had no effect on infection by the third day after inoculation. Thus, when these findings are combined with those of our earlier in vitro studies, in which the involvement of viral TF was studied 1 h after inoculation [23] , a compartmentalized model emerges. First, early in the infection cycle, when the virus initially docks with the target cell, envelope TF enhances infection through PAR2, which requires FXa, as shown by in vitro studies [23] . Thus, when TFspecific, FXa-specific or thrombin-specific anticoagulants ; n = 8, gray bar, as in Fig. 3 ) herpes simplex virus type 1 via the tail vein were compared with PAR2 knockout (KO) (PAR2 À ; n = 6) mice and the combined effect of PAR2 KO and viral TF deficiency (n = 5). Three days after inoculation, the mice were processed, and the amounts of infectious virus (Virus; PFUs per milligram) or genome copies (Genome; genome copies per milligram) was determined. In all panels, data are expressed as mean AE standard error of the mean. As determined with Student's t-test, **P ≤ 0.05 and *P ≤ 0.10 as compared with the TF + virus, except for TF
, which is compared with the TF À virus.
were present at the time of mouse inoculation, this first compartment was affected, inhibiting infection. A second compartment is proposed to evolve later in the infection cycle (by the third day) as functional cellular TF induced by infection [57] and virus envelope TF promote FXa and thrombin production, which affect not only the target cell but also additional cells in the circulation. The role of PAR2 may consequently switch from being pro-infection to antiviral. The involvement of PAR2 in influenza A virus (IAV) infection has been studied, and it has been shown to enhance [58, 59] or reduce [60] infection. To explain the inconsistency, cellular protein expression is dynamic during virus infection [44] , suggesting that sampling time or virus load may alter the respective roles of PARs during infection. Like HSV1, IAV is an envelope virus. Therefore, differint envelope factors derived from chicken eggs [61] or canine epithelial cells [62] , such as TF, may also affect the roles of PAR2 during envelope virus infection. The data presented here strongly suggest that hostderived TF on the virus surface and the related production of FXa and thrombin play important roles in HSV1 infection in vivo that involve PAR stimulation. As TF is derived from the host cell where virus replicates, a virus may undergo various envelope surface transformations, depending on the host cell from which it egresses. Acquisition of envelope TF or other as yet unidentified host proteins may promote the infection of previously protected tissue and affect tropism. An example is the brain, which was not infectible in mice unless TF was a constituent of the HSV1 surface, providing an explanation for occurrences of sporadic encephalitis. 
